You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 474.4. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||21.08 mL||105.4 mL||210.79 mL|
|0.5 mM||4.22 mL||21.08 mL||42.16 mL|
|1 mM||2.11 mL||10.54 mL||21.08 mL|
|5 mM||0.42 mL||2.11 mL||4.22 mL|
References are publications that support the biological activity of the product.
Douris (1992) Effects of the putative 5-HT1A receptor antagonist NAN-190 on free feeding and on feeding induced by the 5-HT1A receptor agonist 8-OH-DPAT in the rat. Eur.J.Pharmacol. 219 105 PMID: 1397037
Glennon et al (1988) Arylpiperazine derivatives as high affinity 5-HT1A serotonin ligands. J.Med.Chem. 31 1968 PMID: 3172131
Williams and Glennon (1988) NAN-190: an arylpiperazine analog that antagonizes the stimulus effects of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Eur.J.Pharmacol. 154 339 PMID: 2976673
If you know of a relevant reference for NAN-190 hydrobromide, please let us know.
View Related Products by Product Action
Keywords: NAN-190 hydrobromide, NAN-190 hydrobromide supplier, 5-HT1A, antagonists, Serotonin, Receptors, 5-HT1, NAN190, 0553, Tocris Bioscience
3 Citations for NAN-190 hydrobromide
Citations are publications that use Tocris products. Selected citations for NAN-190 hydrobromide include:
Geerts et al (1999) Involvement of 5-HT1B receptors in collar-induced hypersensitivity to 5-hydroxytryptamine of the rabbit carotid artery. Br J Pharmacol 127 1327 PMID: 10455282
Pagano et al (2008) Gαo/i-stimulated proteosomal degradation of RGS20: a mechanism for temporal integration of Gs and Gi pathways. Physiol Behav 20 1190 PMID: 18407463
Demarque and (2010) Activity-dependent expression of Lmx1b regulates specification of serotonergic neurons modulating swimming behavior. Neuron 67 321 PMID: 20670838
Do you know of a great paper that uses NAN-190 hydrobromide from Tocris? Please let us know.
Reviews for NAN-190 hydrobromide
There are currently no reviews for this product. Be the first to review NAN-190 hydrobromide and earn rewards!
Have you used NAN-190 hydrobromide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.